CanSino COVID-19 Vaccine

CONVIDECIATM is by far China’s only approved single-shot recombinant COVID-19 vaccine (Ad5-nCov) on the market.

CanSino Biologics Inc., a high-tech biological product enterprise specializing in the R&D and production of high-quality vaccines for human use, has a strong research pipeline of 16 vaccines covering 13 infectious diseases which include the globally innovative recombinant Ebola vaccine and the recombinant novel coronavirus vaccine. CONVIDECIATM , approved on February 25th, 2021, has been vaccinated on a massive scale at home and abroad with widely recognized safety and efficacy. Based on the same formula of the injection version, CanSino has developed the world’s first inhaled version of COVID-19 vaccine, and has so far made visible progress in phase-II clinical trial.

The steady progress of our COVID-19 vaccine program is attributable to the assistance and guidance of government departments at various levels, as well as the cooperation and support from research institutions and upstream and downstream enterprises involved in vaccine R&D along the industrial chain.

-- Yu Xuefeng, Co-founder, President and CEO of CanSino Biologics Inc.